Stockreport

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]

Sagimet Biosciences Inc.  (SGMT) 
PDF End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) expected in the second quarter of 2024 Preparations are underway to start a pivotal Phase 3 trial [Read more]